3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Samina Farid of Golden Seeds, Stuart Corr of Pumps & Pipes, and Saniya Mansuri of TMC. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across seed investing, energy tech, and health care.

Samina Farid, head of the Houston Chapter of Golden Seeds

Samina Farid of Golden Seeds joins the Houston Innovators Podcast to discuss opportunities in angel investing. Photo courtesy of Golden Seeds

After working in technology in her home country of Pakistan, Samina Farid, who was raised in the United States, found her way to Houston in the '70s where business was booming.

She was recruited to work at Houston Natural Gas — a company that would later merge and create Enron — where she rose through the ranks and oversaw systems development for the company before taking on a role running the pipelines.

"When you're in technology, you're always looking for inefficiencies, and you always see areas where you can improve," Farid says on the Houston Innovators Podcast, explaining that she moved on from Enron in the mid-'80s, which was an exciting time for the industry.

"We had these silos of data across the industry, and I felt like we needed to be communicating better, having a good source of data, and making sure we weren't continuing to have the problems we were having," she says. "That was really the seed that got me started in the idea of building a company." Read more.

Stuart Corr, executive director of Pumps & Pipes

For the eighteenth year in a row, the annual Pumps & Pipes event will showcase and explore convergence innovation and common technology themes across Houston’s three major industries. Image courtesy of Pumps & Pipes

Every year, Houston's legacy industries — energy, medicine, and aerospace — come together to share innovative ideas and collaborate on future opportunities. The annual Pumps & Pipes event will showcase and explore convergence innovation and common technology themes across Houston’s three major industries.

"With NASA in its backyard, the world’s largest medical center, and a reputation as the 'Energy Capital of the World,' Houston is uniquely positioned to lead in cross-industry convergence innovation and is reflected in the theme of this year’s event – Blueprint Houston: Converge and Innovate," Stuart Corr, executive director of Pumps & Pipes, writes in a guest column about the event. Read more.

Saniya Mansuri, health care consultant for BioPath @ TMC

The goal of the Texas Medical Center's BioPath program is to attract young people considering going into the trades to learn the skills to become biomanufacturing professionals. Photo via TMC

Houston is currently in need of biomanufacturing professionals to keep up with the ever-growing industry. That's what Saniya Mansuri, health care consultant for BioPath @ TMC, says.

“Houston has lost out on a big biopharmaceutical company. And when there was a feasibility study that was done, it was identified that one of the reasons that Houston wasn't chosen was the lack of a workforce and a lack of workforce development programs,” she explains.

Mansuri and the TMC Innovation team are doing just that with the introduction of the new program. She moved from Toronto in 2023. When she applied for a role at TMC Innovation, she was handpicked to help shepherd the BioPath program, thanks to her background that included starting a nonprofit for underserved youth in Canada. Read more.

The goal of the Texas Medical Center's BioPath program is to attract young people considering going into the trades to learn the skills to become biomanufacturing professionals. Photo via TMC

Building a biotech workforce: How this Houston program is shaping the next generation

future focused

Houston is currently in need of biomanufacturing professionals to keep up with the ever-growing industry. That's what Saniya Mansuri, health care consultant for BioPath @ TMC, says.

The goal of the BioPath program is to attract young people considering going into the trades to learn the skills to become biomanufacturing professionals. According to BioPath’s website, 42 percent of TMC institutions anticipate a great need for biotechnicians in the near future, but there’s a lack of places for workers to train that aren’t part of a four-year degree. BioPath not only helps to recruit youths to careers that only require two years of training, but educates them for success in their newly chosen jobs.

“For the role of biomanufacturing technician, you can do a certificate program, get certified and enter into an entry level career that pays upwards of $50,000 — a stable career where there is a lot of development and job mobility involved,” says Mansuri.

This school year saw the debut of a pilot program that began with marketing and awareness to begin to get kids excited. Working with the organization Bridge Year, BioPath has created a booth for career fairs at which there’s a simulation of the skills involved in column chromatography that potential technicians would be learning. The booth is currently touring HISD high schools.

BioPath is also partnering with the national nonprofit, Learning Undefeated, to create a mobile STEM lab that will park at schools starting in January.

“Instead of students going to a biology class, you would swap it out for a class on this mobile STEM lab, and we have a biomanufacturing activity and curriculum that the students would learn,” explains Mansuri.

But that’s only the beginning. BioPath is looking at securing internships for the students, as well as sponsoring interested students in attending a biomanufacturing summer camp run by Texas A&M. Once educated, Mansuri and her team will help their charges with certification, mentorship and finding jobs post-certification.

Mansuri says she’s already received emails from interested students who have taken part in the “Career Test Drive” booth, but expects more after a soft launch in February in which 200 high school students will come to the TMC to learn more. The future for biomanufacturing in Houston is looking more promising already.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME